阿普斯特治疗活动性银屑病关节炎的效果

The effect of Apremilast in the treatment of active psoriatic arthritis: Apremilast is a new oral dosage form of a small molecule substance that specifically targets phosphodiesterase 4. This study mainly evaluates the effectiveness and safety of Apremilast in the treatment of active psoriatic joints (PsA).

This multicenter, randomized, double-blind, placebo-controlled study included the following features: During the 12-week treatment period, patients received placebo, Apremilast 20 mg twice daily, or Apremilast 40 mg once daily; during the 12-week treatment extension period, patients in the placebo group were re-randomized to receive Apremilast. Termination of treatment was followed by a 4-week observation period. The primary endpoint of the study was the proportion of patients achieving a 20% improvement in the American College of Rheumatology criteria (ACR20) at 12 weeks. Safety assessment includes adverse events (AEs), physical examination, vital signs, laboratory parameters and electrocardiogram.

204 PsA patients were randomly assigned to treatment groups, of whom 165 completed the treatment period. At the end of the treatment period (week 12), 43.5% of patients who received apremilast 20 mg twice daily (p<0.001) and 35.8% of patients who received apremilast 40 mg once daily (p=0.002) achieved ACR20 response, compared with 11.8% of patients who received placebo. At the end of the treatment extension period (week 24), more than 40% of patients in each group (those who received apremilast 20 mg twice daily, those who received apremilast 40 mg once daily, and those who originally received placebo were rerandomized to receive apremilast) successfully achieved ACR20 remission. The vast majority of patients in the treatment period (84.3%) and patients in the treatment extension period (68.3%) reported ≥1 AE. The most common adverse reactions reported were diarrhea, headache, rhinitis, nasopharyngitis, and fatigue, most of which were mild to moderate.

The researchers believe that the use of 20 mg twice daily or apremilast 40 mg once daily for the treatment of active PsA has been proven to be effective in placebo controls and is well tolerated by patients. Whether Apremilast can achieve a balance in efficacy, tolerability and safety in the treatment of PsA requires further research.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: